Giustino Varrassi

Introduction: The Gnana laryngeal mask airway II (GLA-II) is a supraglottic airway device similar to the classic laryngeal mask airway, except it has an additional suction port. This suction port allows for the removal of secretions and saliva. A previous version of the Gnana laryngeal airway 4 was made of silicone, while this newer version is made of polyvinyl chloride (PVC), which is more affordable. This study aimed to demonstrate the effectiveness and tolerability of this PVC-designed GLA-II and evaluate its ability to suction secretions.Methods: The prospective cohort study included 100 gastrointestinal (GI) cases to determine the effectiveness and toleration of the GLA-II. The American Society of Anesthesiologists (ASA) class 1-3 patients were evaluated with a Mallampati airway score for GI-related procedures. After anesthesia induction with propofol, the GLA-II was inserted, and the time for successful insertion was recorded. All cases were completed within 62 minutes. During this time, the secretion volumes were also measured.Results: One hundred patients were included in the study: 52% were males and 48% were females. Thirty-four patients were scored as ASA class 1 or 2, while 66 were scored as ASA class 3. The GLA-II insertion was successful on the first attempt in 92 patients, and a second attempt was necessary for six patients. It was unsuccessful in two patients. The average time for successful insertion was 28.3 ± 4.3 seconds. The average amount of saliva suctioned was 9.3 ± 2.6 mL. There were no intraoperative or postoperative complications during these cases.Conclusion: The PVC GLA-II device is distinguished by its ability to allow suctioning during placement. With an adequate epiglottic seal, it can be safely and successfully inserted in a short period of time. More research should be conducted to explore the use of GLA-II devices in other settings, such as emergencies and life-saving scenarios.

Congenital bleeding disorders involve specific deficiencies in factors that can alter hemostasis, increasing the risk of bleeding. This case report describes a patient with Von Willebrand’s disease who was diagnosed with severe thoracic facet arthritis with pain scores of 9/10. An antihemophilic factor (vWF, Humate-P) injection was administered by a hematologist just before thoracic medial branch blocks. Rather than receiving traditional second thoracic medial branch blocks on another day, the patient, after documenting complete relief of his symptoms with 1% lidocaine, received bilateral T6-8 thoracic radiofrequency ablations, which resulted in complete resolution of his symptoms. A second dose of Humate-P was delivered 24 hours post-procedure. Careful planning with hematologists can enable safe and effective interventional pain procedures in patients with congenital hematologic disorders. This appears to be the first case report in world literature of a patient with Von Willebrand’s disease successfully receiving thoracic radiofrequency ablations.

Menopause is characterized by the cessation of menstruation for 12 consecutive months. In this narrative review, we describe the transitional stages of menopause, clinical presentation, pharmacological management of symptoms, and effects on fluctuating hormone levels. To standardize the stages of menopause, the Stages of Reproductive Aging Workshop + 10 (STRAW+10) system was designed with five distinct categories corresponding to symptom presentation and numerical years. Common clinical presentations consist of vasomotor hot flashes, mood changes, decreased libido, osteoporosis, and genitourinary changes, all of which are associated with changes in hormone levels. Because hormones play a major role in the mechanism of menopause, hormone replacement therapy with estrogen, progesterone, or a combination is explored and shown to demonstrate symptom reduction in a large percentage of women. Nonhormonal treatment and alternative therapies are used to treat vasomotor symptoms if contraindications present to hormone therapy or for those who prefer fewer side effects. Thus, many women experience uncomfortable symptoms during menopause, some of which cause significant changes in quality of life. In this regard, understanding the pathophysiology, symptomatology, and current treatment options with side effect profiles allows for continued research and discovery of advanced therapy for treating symptoms to ameliorate discomfort and pain in menopausal women.

Mohs micrographic surgery (MMS) is a precise and effective technique for treating skin cancers, necessitating high accuracy and real-time decision-making to ensure complete tumor removal while preserving healthy tissue. The introduction of the Apple Vision Pro (AVP), an advanced mixed-reality headset, presents a potential technological advancement in surgical practice. The present investigation explores the integration of AVP into Mohs surgery, focusing on its potential to enhance preoperative planning, intraoperative guidance, and postoperative analysis. The AVP’s high-resolution displays, advanced eye-tracking technology, and real-time data overlay capabilities may assist in meticulous surgical planning and execution. In the preoperative phase, AVP enables the creation and manipulation of detailed 3D models, providing comprehensive visualizations of tumor margins and critical structures. During surgery, AVP’s real-time data overlay aids in precise tumor excision and spatial orientation, reducing errors and improving outcomes. Postoperatively, the AVP facilitates detailed procedural reviews and serves as a robust educational tool for surgical trainees. Despite its promising applications, challenges such as real-time resolution limitations, potential eye strain from prolonged use, and high costs must be addressed for widespread clinical adoption. This review highlights the transformative potential of AVP in Mohs surgery and underscores the need for further research to optimize integration and maximize benefits in dermatological procedures.

Cardiovascular diseases represent the largest worldwide cause of morbidity and mortality. Common signs and symptoms of cardiovascular disease are well characterized and taught in medical curricula, allowing clinicians to quickly recognize and diagnose the more acute and emergent cardiovascular diseases. Dermatological features associated with cardiovascular diseases are less understood but very valuable to appreciate in clinical practice. The present investigation evaluates heart conditions such as heart failure, atherosclerosis, infective endocarditis, and Takotsubo cardiomyopathy, highlighting dermatologic signs that indicate underlying cardiovascular pathology and serve as important diagnostic and prognostic markers.

Introduction: Head and neck cancer (HNC) patients may experience neuropathic pain (NP) due to radiotherapy (RT), which may become chronic. Pregabalin, an anticonvulsant, alters the transmission of painful stimuli at the synaptic level, modifying their perception. Pregabalin is used in NP treatment, but limited data exist on RT-treated HNC patients. This retrospective study aimed to present a case series of HNC patients with chronic NP after RT managed with pregabalin.Methods: HNC patients’ records from the Department of Oral Medicine and Pathology and Hospital Dentistry, School of Dentistry, National and Kapodistrian University of Athens (NKUA), were searched. Outcome measures were obtained using the Douleur Neuropathique 4 (DN4) scale for NP and the numeric rating scale (NRS) for pain. The use of additional analgesic medication was also recorded.Results: Five HNC (four oral and one nasopharyngeal cancer) patients (mean age 58.5 years) who had received RT (mean total dose 64.7 gray (Gy)) and developed chronic (i.e., present for at least three months after RT) NP, characterized by a positive DN4 score ≥4, were identified. The initial assessment was five months to six years after RT (mean DN4=4.6±0.89 and mean NRS=6±3.08). “Burning,” “pins and needles,” and “numbness” were the NP descriptors mostly used. Pregabalin was titrated up to 150-300 mg per day; paracetamol and/or tramadol were also administered (daily doses 3000 mg and 100-150 mg, respectively). A substantial pain relief (≥50%) according to the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) (mean DN4=1.6±1.67 and NRS=1.6±1.67) was reported after two to three months of treatment, when tapering was initiated. Two patients (2/5) had complete remission of symptoms (DN4=0, NRS=0). No serious adverse effects were reported; one patient reported excess salivation.Conclusions: Pregabalin may be a promising option for managing RT-related chronic NP in HNC patients. Further studies, including randomized controlled trials on RT-treated HNC patients, should be conducted.

This narrative review examines the role of the Bacillus Calmette-Guérin (BCG) vaccine in global tuberculosis (TB) control efforts, with particular emphasis on the differences in vaccination policies between countries, such as the US, where routine BCG administration is not practiced. A significant complication of the BCG vaccine is false positive results in the tuberculin skin test (TST), often leading to misdiagnoses and unnecessary treatments. To address these issues, interferon-gamma release assays (IGRAs) have emerged as a more specific diagnostic tool that reduces false positives associated with prior BCG vaccination. However, despite advancements, public health challenges persist in accurately detecting latent and active TB, particularly in populations previously vaccinated with BCG. This review synthesizes existing literature to assess these challenges, emphasizing the need for updated policies and improved diagnostic tools for BCG-vaccinated populations in the US and globally. Recommendations include integrating IGRAs into routine practice and tailoring TB control strategies to mitigate the diagnostic complications of BCG.

The present investigation evaluated transcutaneous electrical nerve stimulation (TENS) for the non-pharmacological treatment of post-herpetic neuralgia (PHN). PHN is the most common complication of the Herpes Zoster virus, affecting one in every five patients with shingles, and presents as intense neuropathic pain that can persist for 90 days or longer after the initial onset of symptoms. Current pharmacological treatment options are mainly limited to symptom management, including oral medications such as tricyclic antidepressants and gabapentinoid preparations, as well as topical options such as lidocaine or capsaicin. TENS is a minimally invasive, non-pharmacological electrical nerve stimulation device currently approved for the treatment of neuropathic pain in adults, providing patients with an alternative or adjunct treatment option to medication with a reduced potential for unwanted side effects, drug-drug interactions or potentially life-threatening toxicity. Current indications for the use of TENS in the treatment of PHN are recommended only after therapeutic goals are attempted and unsuccessfully met by current mainstay medications. More research into the efficacy and safety of TENS for treating PHN should be conducted to clarify further its role as a mainstay treatment for this condition.

Systemic lupus erythematosus (SLE) is an autoimmune disease that more commonly affects African American people, although it is seen in people of all racial backgrounds. This condition is characterized by a dysregulated immune response resulting in widespread inflammation. Clinical manifestations caused by this inflammation include arthritis, anemia, cutaneous rashes, pleuritis, and nephritis. Treatment for SLE aims to reduce disease activity and maintain a state of low inflammation. In this regard, numerous treatments are used, such as hydroxychloroquine, glucocorticoids, and non-glucocorticoid immunosuppressants such as methotrexate. Related to these drugs resulting in significant adverse effects and being ineffective in controlling SLE symptoms in some patients, new biologic agents have been created in hopes of better treating SLE. This includes belimumab and anifrolumab, monoclonal antibodies directed against the cytokine, and type 1 interferon receptor, respectively. These agents are indicated in patients with SLE whose symptoms are inadequately controlled by standard therapy alone. Clinical trials have shown that these agents effectively reduce SLE symptoms as judged using standardized metrics of disease activity. These biological agents have also been shown to have generally mild side effects when taken by patients with SLE, making them safe for use. In addition to the above medications, new treatments are being developed for SLE patients, such as cenerimod, litifilimab, chimeric antigen receptor T cells, and DS-7011a (anti-toll-like receptor 7 monoclonal antibody). These new treatments have shown promise in clinical trials. However, more information regarding their safety and efficacy is needed before they are available for the treatment of SLE.

The management of postoperative pain in pediatric patients undergoing emergency surgical procedures, particularly in non-pediatric hospitals, presents significant challenges due to the unique physiological requirements of children. The utilization of opioid analgesia may result in severe complications, necessitating a transition toward multimodal analgesia, which integrates various pain management strategies to enhance effectiveness while mitigating adverse effects. Locoregional anesthesia techniques, such as fascial plane blocks, provide targeted pain alleviation, reducing dependence on opioids. Recent advancements in ultrasound-guided methodologies have markedly improved safety and precision in this context. This report presents two cases involving pediatric patients aged eight and 12 years who underwent urgent posttraumatic open splenectomy. Both patients exhibited stable hemodynamic parameters and had no significant prior medical history. Following surgery, they received an ultrasound-guided rectus sheath block (RSB) and dynamic transversus abdominis plane blocks (TAPBs) utilizing a mixture of ropivacaine, dexamethasone, and clonidine. Fentanyl was administered before and during the surgical procedures, which lasted approximately 75 minutes. Upon regaining consciousness, both patients indicated a visual analog scale (VAS) pain score of 0. They required only a single dose of intravenous acetaminophen for pain relief, demonstrating effective opioid-free pain management and achieving a high level of parental satisfaction. Combined RSB and TAPB provide adequate and safe postoperative pain management for pediatric patients undergoing emergency splenectomy in a non-pediatric hospital setting. This approach can reduce opioid dependence and improve patient outcomes. Further research is warranted to explore the broader application of locoregional anesthesia techniques for pediatric emergency surgery in non-pediatric settings.